ClinicalTrials.gg
RecruitingNCT07628049Updated Oct 1, 2026

A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults

A Phase 1/2 interventional study of RSV/hMPV_V low dose vaccine and RSV/hMPV_V medium dose vaccine in Respiratory Syncytial Virus Infections+Metapneumovirus, sponsored by GlaxoSmithKline. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by GlaxoSmithKline · Phase 1/2, Interventional, and Prevention

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 1, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1,456
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline — 1 open to participants now, 5 under way, 3 of them phase 3. Respiratory Syncytial Virus Infections · GlaxoSmithKline.

Planned enrollment
11th of 40
1,456 · median 642
Started
2026
the only one that year
Phase 1/2
4 of 40
1 open now
Registered
40th of 40
by date

Among the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, this one is the 11th largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 1/2, and was the 40th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline is open now, in 2 countries.

By country, each count listing its studies:

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Respiratory Syncytial Virus Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the safety, reactogenicity, and immune response of the different formulations of the investigational RSV/hMPV combination vaccine and investigational hMPV vaccine in younger and older adults.

03

Conditions studied

  • Respiratory Syncytial Virus Infections+Metapneumovirus

Keywords

  • Safety
  • Reactogenicity
  • Immunogenicity
  • Respiratory syncytial virus (RSV)
  • Human metapneumovirus (hMPV)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Written obtained from the participant prior to performance of any study-specific procedure.
  • Participants who can and will comply with the requirements of the protocol (e.g., completion of the eDiary, return for follow-up visits, ability to access and utilize a phone or other electronic communications).
  • (BMI) between 18 kg/m\^2 and 33 kg/m\^2, inclusive.

Specific inclusion criteria for OA

  • A male or female between and including, 60 to 80 YOA at the time of the study intervention administration.
  • Healthy participants or medically stable patients as established by medical history and physical examination.

Specific inclusion criteria for YA

  • A male or female participant between and including 18 to 49 YOA at the time of the study intervention administration.
  • Healthy participants as established by medical history, clinical examination and laboratory assessment at screening.
  • Participants of non- may be enrolled in the clinical study.
  • Participant of childbearing potential may be enrolled in the study if the participant:

    • has used two methods of , at-least one of which must be a highly effective method, and the other being male condom for male sexual partners of POCBP to be used during sexual intercourse (with the exception of sexual abstinence, vasectomized partner and male partner who has been sterilized, in which case contraception is not required), at-least 30 days prior to study intervention administration, and has agreed to continue using above contraception requirements for 8 weeks after study intervention administration.
    • has a negative serum pregnancy test at screening and negative urine pregnancy test prior to study intervention administration on Day 1.

Exclusion criteria

Exclusion criteria:

Participants are excluded from participating in the study if any of the following criteria apply:

  • History of any reaction or likely to be exacerbated by any component of the study intervention(s).
  • Any medical condition that in the judgment of the investigator would make IM injection unsafe.
  • Any confirmed or suspected or immunodeficient condition resulting from disease (e.g., current , ) or immunosuppressive/cytotoxic therapy (e.g., medication used during cancer chemotherapy, organ transplantation, or to treat disorders), based on medical history and physical examination (no laboratory testing required).
  • Acute or unstable chronic pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination and medical history.
  • Documented history of HIV, , infection.
  • History of RSV and /or hMPV-associated illness, diagnosed serologically or microbiologically in the last 12 months.
  • Recurrent history or uncontrolled neurological disorders or seizures, or history of demyelinating conditions (including GBS).
  • Any history of dementia or any medical condition that moderately or severely impairs cognition.
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the clinical study.
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study (e.g., life-threatening disease).
  • Use of any or non-registered product (drug, vaccine, or invasive medical device) other than the study intervention during the period beginning 30 days before study intervention administration (Day -29 to Day 1), or within 5 half-lives, whichever is longer, or their planned use during the study period.
  • Has previously received an investigational or approved vaccine or antibody for prevention of hMPV and/or RSV-associated diseases.
  • Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the study.

    • Up to 3 months prior to the study intervention administration:

      • For , this will mean prednisone equivalent >=20 mg/day for adult participants. Inhaled, topical and intra-articular steroids are allowed.
      • Administration of immunoglobulins and/or any blood products or plasma derivatives.
    • Up to 6 months prior to study intervention administration: long-acting immune-modifying drugs including among others immunotherapy (e.g., TNF-inhibitors), monoclonal antibodies, antitumoral medication.
  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention.
  • History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
  • Participation of any study personnel or their immediate dependents, family, or household members.
  • Planned move during the study period that will prohibit participating in the study until study end.
  • Bedridden participants.

Specific exclusion criteria for OA population

  • Planned or actual administration of a vaccine not foreseen by the study protocol in the period beginning 30 days before study intervention administration (Day - 29 to Day 1), or their planned use 30 days after study intervention administration, with the exception of inactivated, subunit and split influenza vaccines or COVID-19 vaccines which can be administered up to 14 days before or from 14 days after the study intervention administration.
  • At screening (Phase 1 only), participants with:

    • >=Grade 2 abnormalities for the following parameters, regardless of clinical significance, should be excluded:

      • Hematologic: (Hb), white blood cells (WBC), , absolute cell counts of lymphocytes, neutrophils, eosinophils,
      • Biochemical: (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), , creatinine, blood urea nitrogen (BUN).
    • Grade 1/mild hematologic and/ or biochemical laboratory abnormalities that are not in the clinical judgment of the investigator, may be included.

Specific exclusion criteria for YA population

  • Pregnant or lactating participant.
  • Female planning to become pregnant or planning to discontinue precautions for 8 weeks after study intervention administration.
  • Planned or actual administration of a vaccine not foreseen by the study protocol in the period beginning 30 days before study intervention administration (Day - 29 to Day 1), or their planned use 30 days after study intervention administration.
  • At screening, participants with:

    • >=Grade 2 abnormalities for the following parameters, regardless of clinical significance, should be excluded:

      • Hematologic: Hb, WBC, platelets, absolute cell counts of lymphocytes, neutrophils, eosinophils,
      • Biochemical: ALT, AST, ALP, bilirubin, creatinine, BUN.
    • Grade 1/mild hematologic and/ or biochemical laboratory abnormalities that are not clinically significant in the clinical judgment of the investigator, may be included.
  • Use of any medication, including prescription and non-prescription drugs or herbal remedies (such as St. John's wort) beginning 14 days (or 5 half-lives) prior to study intervention administration and/or planned administration during the study period. Certain medications may be permitted (Eg: contraceptives for POCBP).
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,456 participants (estimated)

Study arms

  • Experimental
    RSV/hMPV_X_low dose_Ph1_Younger Adults (YA) Group

    YA participants receive a single dose of RSV/hMPV\_X low dose vaccine in Phase 1, at Day 1.

    Biological: RSV/hMPV_X low dose vaccine

  • Experimental
    RSV/hMPV_X_medium dose_Ph1_YA Group

    YA participants receive a single dose of RSV/hMPV\_X medium dose vaccine in Phase 1, at Day 1.

    Biological: RSV/hMPV_X medium dose vaccine

  • Experimental
    RSV/hMPV_X_high dose_Ph1_YA Group

    YA participants receive a single dose of RSV/hMPV\_X high dose vaccine in Phase 1, at Day 1.

    Biological: RSV/hMPV_X high dose vaccine

  • Experimental
    hMPV_Y_high dose_Ph1_YA Group

    YA participants receive a single dose of hMPV\_Y high dose vaccine in Phase 1, at Day 1.

    Biological: hMPV_Y high dose vaccine

  • Experimental
    hMPV_Z_low dose_Ph1_YA Group

    YA participants receive a single dose of hMPV\_Z low dose vaccine in Phase 1, at Day 1.

    Biological: hMPV_Z low dose vaccine

  • Experimental
    hMPV_Z_medium dose_Ph1_YA Group

    YA participants receive a single dose of hMPV\_Z medium dose vaccine in Phase 1, at Day 1.

    Biological: hMPV_Z medium dose vaccine

  • Experimental
    hMPV_Z_high dose_Ph1_YA Group

    YA participants receive a single dose of hMPV\_Z high dose vaccine in Phase 1, at Day 1.

    Biological: hMPV_Z high dose vaccine

  • Active comparator
    Control Vaccine_Ph1_YA Group

    YA participants receive a single dose of control vaccine in Phase 1, at Day 1.

    Biological: Control vaccine

  • Placebo comparator
    Placebo_Ph1_YA Group

    YA participants receive a single dose of placebo in Phase 1, at Day 1.

    Combination Product: Placebo

  • Experimental
    RSV/hMPV_V_low dose_Ph1 and Ph2_Older Adults (OA) Group

    OA participants receive a single dose of RSV/hMPV\_V low dose vaccine in both Phase 1 and Phase 2, at Day 1.

    Biological: RSV/hMPV_V low dose vaccine

  • Experimental
    RSV/hMPV_V_medium dose_Ph1 and Ph2_OA Group

    OA participants receive a single dose of RSV/hMPV\_V medium dose vaccine in both Phase 1 and Phase 2, at Day 1.

    Biological: RSV/hMPV_V medium dose vaccine

  • Experimental
    RSV/hMPV_V_high dose_Ph1 and Ph2_OA Group

    OA participants receive a single dose of RSV/hMPV\_V high dose vaccine in both Phase 1 and Phase 2, at Day 1.

    Biological: RSV/hMPV_V high dose vaccine

  • Experimental
    RSV/hMPV_W_low dose_Ph1 and Ph2_OA Group

    OA participants receive a single dose of RSV/hMPV\_W low dose vaccine in both Phase 1 and Phase 2, at Day 1.

    Biological: RSV/hMPV_W low dose vaccine

  • Experimental
    RSV/hMPV_W_medium dose_Ph1 and Ph2_OA Group

    OA participants receive a single dose of RSV/hMPV\_W medium dose vaccine in both Phase 1 and Phase 2, at Day 1.

    Biological: RSV/hMPV_W medium dose vaccine

  • Experimental
    RSV/hMPV_W_high dose_Ph1 and Ph2_OA Group

    OA participants receive a single dose of RSV/hMPV\_W high dose vaccine in both Phase 1 and Phase 2, at Day 1.

    Biological: RSV/hMPV_W high dose vaccine

  • Experimental
    RSV/hMPV_X_low dose_Ph1 and Ph2_OA Group

    OA participants receive a single dose of RSV/hMPV\_X low dose vaccine in both Phase 1 and Phase 2, at Day 1.

    Biological: RSV/hMPV_X low dose vaccine

  • Experimental
    RSV/hMPV_X_medium dose_Ph1 and Ph2_OA Group

    OA participants received a single dose of RSV/hMPV\_X medium dose vaccine in both Phase 1 and Phase 2, at Day 1.

    Biological: RSV/hMPV_X medium dose vaccine

  • Experimental
    RSV/hMPV_X_high dose_Ph1 and Ph2_OA Group

    OA participants receive a single dose of RSV/hMPV\_X high dose vaccine in both Phase 1 and Phase 2, at Day 1.

    Biological: RSV/hMPV_X high dose vaccine

  • Experimental
    hMPV_Y_low dose_Ph1_OA Group

    OA participants receive a single dose of hMPV\_Y low dose vaccine in Phase 1, at Day 1.

    Biological: hMPV_Y low dose vaccine

  • Experimental
    hMPV_Y_medium dose_Ph1 and Ph2_OA Group

    OA participants receive a single dose of hMPV\_Y medium dose vaccine in both Phase 1 and Phase 2, at Day 1.

    Biological: hMPV_Y medium dose vaccine

  • Experimental
    hMPV_Y_high dose_Ph1 and Ph2_OA Group

    OA participants receive a single dose of hMPV\_Y high dose vaccine in both Phase 1 and Phase 2, at Day 1.

    Biological: hMPV_Y high dose vaccine

  • Experimental
    hMPV_Z_low dose_Ph1_OA Group

    OA participants receive a single dose of hMPV\_Z low dose vaccine in Phase 1, at Day 1.

    Biological: hMPV_Z low dose vaccine

  • Experimental
    hMPV_Z_medium dose_Ph1_OA Group

    OA participants receive a single dose of hMPV\_Z medium dose vaccine in Phase 1, at Day 1.

    Biological: hMPV_Z medium dose vaccine

  • Experimental
    hMPV_Z_high dose_Ph1_OA Group

    OA participants receive a single dose of hMPV\_Z high dose vaccine in Phase 1, at Day 1.

    Biological: hMPV_Z high dose vaccine

  • Active comparator
    Control Vaccine_Ph1 and Ph2_OA Group

    OA participants receive a single dose of control vaccine in both Phase 1 and Phase 2, at Day 1.

    Biological: Control vaccine

  • Placebo comparator
    Placebo_Ph1 and Ph2_OA Group

    OA participants receive a single dose of placebo in both Phase 1 and Phase 2, at Day 1.

    Combination Product: Placebo

Interventions

  • BiologicalRSV/hMPV_V low dose vaccine

    RSV/hMPV\_V low dose vaccine administered intramuscularly.

  • BiologicalRSV/hMPV_V medium dose vaccine

    RSV/hMPV\_V medium dose vaccine administered intramuscularly.

  • BiologicalRSV/hMPV_V high dose vaccine

    RSV/hMPV\_V high dose vaccine administered intramuscularly.

  • BiologicalRSV/hMPV_W low dose vaccine

    RSV/hMPV\_W low dose vaccine administered intramuscularly.

  • BiologicalRSV/hMPV_W medium dose vaccine

    RSV/hMPV\_W medium dose vaccine administered intramuscularly.

  • BiologicalRSV/hMPV_W high dose vaccine

    RSV/hMPV\_W high dose vaccine administered intramuscularly.

  • BiologicalRSV/hMPV_X low dose vaccine

    RSV/hMPV\_X low dose vaccine administered intramuscularly.

  • BiologicalRSV/hMPV_X medium dose vaccine

    RSV/hMPV\_X medium dose vaccine administered intramuscularly.

  • BiologicalRSV/hMPV_X high dose vaccine

    RSV/hMPV\_X high dose vaccine administered intramuscularly.

  • BiologicalhMPV_Y low dose vaccine

    hMPV\_Y low dose vaccine administered intramuscularly.

  • BiologicalhMPV_Y medium dose vaccine

    hMPV\_Y medium dose vaccine administered intramuscularly.

  • BiologicalhMPV_Y high dose vaccine

    hMPV\_Y high dose vaccine administered intramuscularly.

  • BiologicalhMPV_Z low dose vaccine

    hMPV\_Z low dose vaccine administered intramuscularly.

  • BiologicalhMPV_Z medium dose vaccine

    hMPV\_Z medium dose vaccine administered intramuscularly.

  • BiologicalhMPV_Z high dose vaccine

    hMPV\_Z high dose vaccine administered intramuscularly.

  • BiologicalControl vaccine

    Control vaccine administered intramuscularly.

  • Combination productPlacebo

    Placebo administered intramuscularly.

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Solicited Administration Site Events

    Solicited administration site events include pain, redness (erythema) and swelling at administration site.

    Time frame: Day 1 to Day 7

  2. Number of Participants Reporting Solicited Systemic Events

    Solicited systemic events include fever \[defined as oral or axillary temperature greater than or equal to (\>=) 38.0°C/100.4°F\], headache, myalgia (muscle pain), arthralgia (joint pain) and fatigue (tiredness).

    Time frame: Day 1 to Day 7

  3. Number of Participants Reporting Unsolicited Adverse Events (AEs)

    An unsolicited AE is defined as an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow up for solicited events. Unsolicited AEs include both serious and non-serious AEs.

    Time frame: Day 1 to Day 30

  4. Number of Participants Reporting Medically Attended Adverse Events (MAAEs)

    MAAE is defined as unscheduled visit to or from healthcare professional for any reason, including emergency room visits.

    Time frame: Day 1 to Month 12

  5. Number of Participants Reporting Potential immune-mediated disorders (pIMDs)

    pIMDs are a subset of AEs of Special Interest (AESIs) that include autoimmune disorders and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

    Time frame: Day 1 to Month 12

  6. Number of Participants Reporting Serious Adverse Events (SAEs)

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is an abnormal pregnancy outcome, or is a suspected transmission of any infectious agent via an authorized medicinal product.

    Time frame: Day 1 to study end [Month 24 for OA groups (only the selected formulation group & its comparators) and Month 12 for all other YA groups & OA groups]

  7. Number of Participants Reporting Hematological and Biochemical Laboratory Abnormalities

    Time frame: At Day 1 (pre-vaccination) in Phase 1 groups

  8. Number of Participants Reporting Hematological and Biochemical Laboratory Abnormalities

    Time frame: At Day 8 (post-vaccination) in Phase 1 groups

Secondary outcomes

  1. Number of participants with hMPV neutralization titers equal to or above (>=) the assay cut-off value

    Time frame: At Day 1 (pre-vaccination), Day 8 and Day 31 in OA groups included in both Phase 1 and Phase 2

  2. Geometric mean titers (GMTs) of hMPV neutralization titers

    Time frame: At Day 1 (pre-vaccination), Day 8 and Day 31 in OA groups included in both Phase 1 and Phase 2

  3. Mean geometric increase (MGI) of hMPV neutralization titers

    Time frame: At Day 8 and Day 31 compared to Day 1 (pre-vaccination) in OA groups included in both Phase 1 and Phase 2

  4. Seroresponse rate (SRR) against hMPV

    SRR is defined as the number of participants having \>=4-fold increase post-vaccination in neutralization titers against hMPV.

    Time frame: At Day 8 and Day 31 compared to Day 1 (pre-vaccination) in OA groups included in both Phase 1 and Phase 2

  5. Number of participants with RSV-A neutralization titers >= assay cut-off value

    Time frame: At Day 1 (pre-vaccination), Day 8 and Day 31 in OA groups included in both Phase 1 and Phase 2

  6. GMTs of RSV-A neutralization titers

    Time frame: At Day 1 (pre-vaccination), Day 8 and Day 31 in OA groups included in both Phase 1 and Phase 2

  7. MGI of RSV-A neutralization titers

    Time frame: At Day 8 and Day 31 compared to Day 1 (pre-vaccination) in OA groups included in both Phase 1 and Phase 2

  8. SRR against RSV-A

    SRR is defined as number of participants having \>=4-fold-increase post-vaccination in neutralization titers against RSV-A.

    Time frame: At Day 8 and Day 31 compared to Day 1 (pre-vaccination) in OA groups included in both Phase 1 and Phase 2

  9. Number of participants with RSV-B neutralization titers >= assay cut-off value

    Time frame: At Day 1 (pre-vaccination), Day 8 and Day 31 in OA groups included in both Phase 1 and Phase 2

  10. GMTs of RSV-B neutralization titers

    Time frame: At Day 1 (pre-vaccination), Day 8 and Day 31 in OA groups included in both Phase 1 and Phase 2

  11. MGI of RSV-B neutralization titers

    Time frame: At Day 8 and Day 31 compared to Day 1 (pre-vaccination) in OA groups included in both Phase 1 and Phase 2

  12. SRR against RSV-B

    SRR is defined as number of participants having \>=4-fold-increase post-vaccination in neutralization titers against RSV-B.

    Time frame: At Day 8 and Day 31 compared to Day 1 (pre-vaccination) in OA groups included in both Phase 1 and Phase 2

07

Study locations

5 of 5 sites recruiting
  • GSK Investigational Site
    Stockbridge, Georgia 30281-9054, United States
    Recruiting
  • GSK Investigational Site
    Lenexa, Kansas 66219, United States
    Recruiting
  • GSK Investigational Site
    Seattle, Washington 98104-2725, United States
    Recruiting
  • GSK Investigational Site
    Botany, New South Wales 2019, Australia
    Recruiting
  • GSK Investigational Site
    Camberwell, Victoria 3124, Australia
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Apr 2029, 34 months after the start.

Of 16 phase 1/2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's planned 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jun 4, 2026
StartActual
Jun 5, 2026
Primary completionEst.
Apr 5, 2029
CompletionEst.
Apr 5, 2029
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • GSK Investigational Site · Stockbridge, United States
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    1 site added
    Show site
    • GSK Investigational Site · Stockbridge, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07628049
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Jun 5, 2026
Primary completion
Apr 5, 2029 (estimated)
Completion
Apr 5, 2029 (estimated)
Last update
Oct 1, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion